Prophase Labs Inc. (PRPH) 1.40 $PRPH
ProPhase Labs Reports Financial Results for the Three Months Ended March 31, 2016
Marketwired - Tue May 10, 3:10PM CDT
DOYLESTOWN, PA--(Marketwired - May 10, 2016) - ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) today reported its net sales were $5.4 million for the three months ended March 31, 2016 as compared to net sales of $5.9 million for the three months ended March 31, 2015. The Company incurred a net loss for the three months ended March 31, 2016, of $1.3 million, or ($0.08) per share, compared to a net loss of $1.4 million, or ($0.09) per share, for the three months ended March 31, 2015.
PRPH: 1.40 (-0.06)
ProPhase Labs (Nasdaq: PRPH) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Apr 07, 9:00AM CDT
What:
PRPH: 1.40 (-0.06), NDAQ: 63.09 (+0.12)
ProPhase Labs Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
Marketwired - Tue Mar 29, 8:56AM CDT
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) today reported its net sales were $8.2 million for the three months ended December 31, 2015, as compared to net sales of $9.0 for the three months ended December 31, 2014. The Company incurred a net loss for the three months ended December 31, 2015 of $1.3 million, or ($0.07) per share, compared to a net loss of $676,000, or ($0.05) per share, for the three months ended December 31, 2014.
PRPH: 1.40 (-0.06)
ProPhase Labs to Release Fourth Quarter/Year End Results on Tuesday, March 29th
Marketwired - Fri Mar 25, 7:00AM CDT
ProPhase Labs (NASDAQ: PRPH) announced today that financial results for the fourth quarter, ended December 31, 2015, will be released before the market opens on Tuesday, March 29, 2016. A conference call will be held later that morning on March 29th, at 11:00am EST. ProPhase Labs Chairman and CEO, Ted Karkus, and COO/CFO Robert Cuddihy will provide a company overview including a review of activities and fourth quarter results. There will be a question and answer session following initial remarks.
PRPH: 1.40 (-0.06)
ProPhase Labs Discusses the Current Cold Season and Announces Launch of New Product Line, TK Supplements
Marketwired - Wed Jan 13, 5:47PM CST
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) today noted that key industry statistics reveal that according to IMS Health, the incidence of upper respiratory illness across the country has been down double digits for the current cold season(1) to date compared to the prior year cold season. For the week ending December 31, 2015, cold and flu related illnesses are down approximately 25% as compared to the week ending December 31, 2014.
PRPH: 1.40 (-0.06)
BUYINS.NET: PRPH SqueezeTrigger Price is $1.48. There is $28,950 That Short Sellers Still Need To Cover.
M2 - Fri Dec 18, 2:35AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring Prophase Labs Inc (NASDAQ
RPH) in real time and just received an alert that PRPH is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 19300 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $1.48. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
PRPH: 1.40 (-0.06)
BUYINS.NET: PRPH SqueezeTrigger Price is $1.48. There is $23,104 That Short Sellers Still Need To Cover.
M2 - Thu Dec 03, 5:49AM CST
November 30, 2015
PRPH: 1.40 (-0.06)
ProPhase Labs Reports Financial Results for the Three and Nine Months Ended September 30, 2015
Marketwired - Thu Nov 12, 7:01AM CST
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) today reported its net sales were $4.4 million for the three months ended September 30, 2015, as compared to net sales of $5.1 million for the three months ended September 30, 2014. The Company realized net income for the three months ended September 30, 2015 of $602,000, or $0.04 per share, compared to a net loss of $3.2 million, or ($0.18) per share, for the three months ended September 30, 2014.
PRPH: 1.40 (-0.06)
ProPhase Labs, Inc. (Nasdaq RPH) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Sep 17, 10:01AM CDT
What:
PRPH: 1.40 (-0.06), NDAQ: 63.09 (+0.12)
ProPhase Labs incurs lower net loss of USD1.6m for three months ended 30 June 2015
M2 - Thu Aug 13, 3:29AM CDT
Medical science company ProPhase Labs (NASDAQ RPH) disclosed on Wednesday that it recorded a net loss of USD1.6m (USD0.10) per share) for the three months ended 30 June 2015.
PRPH: 1.40 (-0.06)
ProPhase Labs Reports Financial Results for the Three and Six Months Ended June 30, 2015
Marketwired - Wed Aug 12, 7:00AM CDT
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) today reported its net sales were $2.2 million for the three months ended June 30, 2015, as compared to net sales of $1.8 million for the three months ended June 30, 2014. The Company realized a net loss for the three months ended June 30, 2015 of $1.6 million, or ($0.10) per share, compared to a net loss of $3.1 million, or ($0.19) per share, for the three months ended June 30, 2014.
PRPH: 1.40 (-0.06)
BUYINS.NET: PRPH SqueezeTrigger Price is $1.48. There is $34,650 That Short Sellers Still Need To Cover.
M2 - Fri Aug 07, 2:45AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Prophase Labs Inc (NASDAQ RPH) in real time and just received an alert that PRPH is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 22500 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $1.48. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
PRPH: 1.40 (-0.06)
ProPhase Establishes 3.2 Million Share Equity Line
Marketwired - Wed Aug 05, 11:57AM CDT
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) announced today that as of July 30, 2015, it entered into an Investment Agreement (the "Investment Agreement"
with Dutchess Opportunity Fund, II, LP, a Delaware limited partnership ("Dutchess" . Pursuant to the Investment Agreement, Dutchess committed to purchase, subject to certain restrictions and conditions, up to 3,200,000 shares of the Company's common stock, over a period of 36 months from the first trading day following the effectiveness of the registration statement registering the resale of shares purchased by Dutchess pursuant to the Investment Agreement.
PRPH: 1.40 (-0.06)
ProPhase Labs' net loss widens to USD1.4m in the three months ended 31 March 2015
M2 - Thu May 14, 4:24AM CDT
Medical science company ProPhase Labs (NASDAQ RPH) disclosed on Wednesday that it recorded a net loss of USD1.4m (USD0.09 per share) for the three months ended 31 March 2015.
PRPH: 1.40 (-0.06)
ProPhase Labs Reports Financial Results for the Three Months Ended March 31, 2016
Marketwired - Tue May 10, 3:10PM CDT
DOYLESTOWN, PA--(Marketwired - May 10, 2016) - ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) today reported its net sales were $5.4 million for the three months ended March 31, 2016 as compared to net sales of $5.9 million for the three months ended March 31, 2015. The Company incurred a net loss for the three months ended March 31, 2016, of $1.3 million, or ($0.08) per share, compared to a net loss of $1.4 million, or ($0.09) per share, for the three months ended March 31, 2015.
PRPH: 1.40 (-0.06)
ProPhase Labs (Nasdaq: PRPH) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Apr 07, 9:00AM CDT
What:
PRPH: 1.40 (-0.06), NDAQ: 63.09 (+0.12)
ProPhase Labs Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
Marketwired - Tue Mar 29, 8:56AM CDT
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) today reported its net sales were $8.2 million for the three months ended December 31, 2015, as compared to net sales of $9.0 for the three months ended December 31, 2014. The Company incurred a net loss for the three months ended December 31, 2015 of $1.3 million, or ($0.07) per share, compared to a net loss of $676,000, or ($0.05) per share, for the three months ended December 31, 2014.
PRPH: 1.40 (-0.06)
ProPhase Labs to Release Fourth Quarter/Year End Results on Tuesday, March 29th
Marketwired - Fri Mar 25, 7:00AM CDT
ProPhase Labs (NASDAQ: PRPH) announced today that financial results for the fourth quarter, ended December 31, 2015, will be released before the market opens on Tuesday, March 29, 2016. A conference call will be held later that morning on March 29th, at 11:00am EST. ProPhase Labs Chairman and CEO, Ted Karkus, and COO/CFO Robert Cuddihy will provide a company overview including a review of activities and fourth quarter results. There will be a question and answer session following initial remarks.
PRPH: 1.40 (-0.06)
ProPhase Labs Discusses the Current Cold Season and Announces Launch of New Product Line, TK Supplements
Marketwired - Wed Jan 13, 5:47PM CST
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) today noted that key industry statistics reveal that according to IMS Health, the incidence of upper respiratory illness across the country has been down double digits for the current cold season(1) to date compared to the prior year cold season. For the week ending December 31, 2015, cold and flu related illnesses are down approximately 25% as compared to the week ending December 31, 2014.
PRPH: 1.40 (-0.06)
BUYINS.NET: PRPH SqueezeTrigger Price is $1.48. There is $28,950 That Short Sellers Still Need To Cover.
M2 - Fri Dec 18, 2:35AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring Prophase Labs Inc (NASDAQ
RPH) in real time and just received an alert that PRPH is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 19300 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $1.48. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com . PRPH: 1.40 (-0.06)
BUYINS.NET: PRPH SqueezeTrigger Price is $1.48. There is $23,104 That Short Sellers Still Need To Cover.
M2 - Thu Dec 03, 5:49AM CST
November 30, 2015
PRPH: 1.40 (-0.06)
ProPhase Labs Reports Financial Results for the Three and Nine Months Ended September 30, 2015
Marketwired - Thu Nov 12, 7:01AM CST
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) today reported its net sales were $4.4 million for the three months ended September 30, 2015, as compared to net sales of $5.1 million for the three months ended September 30, 2014. The Company realized net income for the three months ended September 30, 2015 of $602,000, or $0.04 per share, compared to a net loss of $3.2 million, or ($0.18) per share, for the three months ended September 30, 2014.
PRPH: 1.40 (-0.06)
ProPhase Labs, Inc. (Nasdaq
RPH) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire - Thu Sep 17, 10:01AM CDT
What:
PRPH: 1.40 (-0.06), NDAQ: 63.09 (+0.12)
ProPhase Labs incurs lower net loss of USD1.6m for three months ended 30 June 2015
M2 - Thu Aug 13, 3:29AM CDT
Medical science company ProPhase Labs (NASDAQ
RPH) disclosed on Wednesday that it recorded a net loss of USD1.6m (USD0.10) per share) for the three months ended 30 June 2015. PRPH: 1.40 (-0.06)
ProPhase Labs Reports Financial Results for the Three and Six Months Ended June 30, 2015
Marketwired - Wed Aug 12, 7:00AM CDT
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) today reported its net sales were $2.2 million for the three months ended June 30, 2015, as compared to net sales of $1.8 million for the three months ended June 30, 2014. The Company realized a net loss for the three months ended June 30, 2015 of $1.6 million, or ($0.10) per share, compared to a net loss of $3.1 million, or ($0.19) per share, for the three months ended June 30, 2014.
PRPH: 1.40 (-0.06)
BUYINS.NET: PRPH SqueezeTrigger Price is $1.48. There is $34,650 That Short Sellers Still Need To Cover.
M2 - Fri Aug 07, 2:45AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Prophase Labs Inc (NASDAQ
RPH) in real time and just received an alert that PRPH is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 22500 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $1.48. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com . PRPH: 1.40 (-0.06)
ProPhase Establishes 3.2 Million Share Equity Line
Marketwired - Wed Aug 05, 11:57AM CDT
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) announced today that as of July 30, 2015, it entered into an Investment Agreement (the "Investment Agreement"
with Dutchess Opportunity Fund, II, LP, a Delaware limited partnership ("Dutchess" . Pursuant to the Investment Agreement, Dutchess committed to purchase, subject to certain restrictions and conditions, up to 3,200,000 shares of the Company's common stock, over a period of 36 months from the first trading day following the effectiveness of the registration statement registering the resale of shares purchased by Dutchess pursuant to the Investment Agreement. PRPH: 1.40 (-0.06)
ProPhase Labs' net loss widens to USD1.4m in the three months ended 31 March 2015
M2 - Thu May 14, 4:24AM CDT
Medical science company ProPhase Labs (NASDAQ
RPH) disclosed on Wednesday that it recorded a net loss of USD1.4m (USD0.09 per share) for the three months ended 31 March 2015. PRPH: 1.40 (-0.06)
